Beta-sitosterol

View my plan →

The short answer

Can modestly improve urinary symptom scores in benign prostatic enlargement without shrinking the prostate.

Evidence and scope: Supported for specific outcomes
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: Evidence supports a specific outcome, not a general wellness or longevity effect.
Before deciding: Key concern: Sitosterolemia, lipid medicines, prostate-cancer evaluation, and carotenoid absorption require review.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Urinary symptoms60–130 mg/day beta-sitosterol in divided doses in trials

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityFat-soluble / lipid-based

Fat-soluble or lipid-based. Absorption generally improves with a meal containing fat.

How it is commonly taken

Take with meals containing fat.

Do not combine casually

Sitosterolemia, lipid medicines, prostate-cancer evaluation, and carotenoid absorption require review.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

1research papers in this ledger

4unique primary studies represented

519unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

1999

Mixed or qualifiedPMID 10368239

Beta-sitosterol for symptomatic benign prostatic hyperplasia

Some preparations improved symptom scores, peak flow, and residual urine but did not reduce prostate size; one glucoside preparation did not improve flow. The small, short, old trials do not establish long-term progression prevention or equivalence to current medication.

Published: 1999Duration: 4–26 weeksn=519 participants4 primary studies represented

Study design and methods

Design: Systematic review of 4 double-blind randomized trials
Population: 519 men with symptomatic benign prostatic hyperplasia
Intervention: Different beta-sitosterol preparations versus placebo
Outcome: Urinary symptom scores, peak flow, residual urine, prostate size, and withdrawals

Open research record ↗

Unscreened discovery appendix—not evidence7 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewPubMed bounded human-evidence search Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.